News
TLPPF
10.26
NaN%
--
Weekly Report: what happened at TLPPF last week (0504-0508)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG) and Telix Pharmaceuticals (OtherTLPPF)
TipRanks · 05/08 02:10
Telix Issues New Shares to Complete Deferred ImaginAb Acquisition Payment
TipRanks · 05/08 01:21
Telix Seeks ASX Quotation for Additional Ordinary Shares
TipRanks · 05/08 01:07
Challenger exits substantial holder position in Telix Pharmaceuticals
TipRanks · 05/06 06:54
Morgan Stanley Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TipRanks · 05/06 01:36
Canaccord Genuity Remains a Buy on Telix Pharmaceuticals (TLPPF)
TipRanks · 05/04 23:37
Weekly Report: what happened at TLPPF last week (0427-0501)?
Weekly Report · 05/04 09:34
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Barchart · 04/30 16:43
Telix to Release Escrowed Shares from Lightpoint Acquisition
TipRanks · 04/29 08:08
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), NeoGenomics (NEO)
TipRanks · 04/29 00:50
Telix to Spotlight Next‑Generation PSMA Therapy Portfolio in Investor Webinar
TipRanks · 04/27 23:34
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
Barchart · 04/27 18:27
Weekly Report: what happened at TLPPF last week (0420-0424)?
Weekly Report · 04/27 09:35
Telix Pharmaceuticals Issues New Tranche of Unquoted Convertible Notes
TipRanks · 04/23 01:17
Telix Reshapes Capital Structure With US$600m Convertible Issue and Bond Buyback
TipRanks · 04/23 00:04
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Barchart · 04/21 15:49
Telix Sets Hybrid 2026 AGM to Engage Global Investor Base
TipRanks · 04/20 22:44
Weekly Report: what happened at TLPPF last week (0413-0417)?
Weekly Report · 04/20 09:34
Telix raises US$600m via new convertible notes to refinance 2029 bonds
TipRanks · 04/20 07:19
More
Webull provides a variety of real-time TLPPF stock news. You can receive the latest news about Telix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TLPPF
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.